Limits...
c-erbB-2 protein expression in astrocytic tumors of the brain.

Reszeć J, Bernaczyk PS, Milewski R, Chyczewski L, Mariak Z - Med. Sci. Monit. (2011)

Bottom Line: There were no statistically significant differences between the examined groups.The strongest c-erbB-2 immunoexpression was observed in low grade astrocytomas (diffuse astrocytomas G2); in the glioblastoma group the c-erbB-2 protein expression was weak and 17.4% of cases were negative.C-erbB-2 protooncogene alteration is an early phenomenon in glial tumor development and progression.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland. joannareszec@gmail.com

ABSTRACT

Background: Astrocytic tumors are the primary brain tumors, which often progress to glioblastoma, a highly malignant neoplasm of the central nervous system. There is much new data regarding to the formation and progression of these tumors; however, glioblastoma remains one of the most fatal neoplasms in humans. The aim of the study was to evaluate the role of c-erbB-2 protein expression in various groups of astrocytic tumors.

Material/methods: 65 cases of astrocytic tumors were divided into 3 groups: diffuse astrocytoma (group I; n=17 cases), anaplastic astrocytoma (group II; n=23 cases) and glioblastoma (group III; n=25 cases). C-erbB-2 protein expression was estimated semiquantitatively on immunohistochemically stained tissue sections using antibodies against c-erbB-2 protein. Statistical analysis was performed in all examined groups.

Results: The c-erbB-2 protein expression was observed in 15 out of 17 cases (88.3%) in group I, 22 out of 25 cases (88%) cases in group II, and in 19 out of 23 cases (82.6%) in group III. There were no statistically significant differences between the examined groups. The strongest c-erbB-2 immunoexpression was observed in low grade astrocytomas (diffuse astrocytomas G2); in the glioblastoma group the c-erbB-2 protein expression was weak and 17.4% of cases were negative.

Conclusions: C-erbB-2 protooncogene alteration is an early phenomenon in glial tumor development and progression.

Show MeSH

Related in: MedlinePlus

Strong positive c-erbB-2 immunoexpression in neoplastic cells of astrocytoma G2. Magn 400×.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3539622&req=5

f2-medscimonit-17-8-br216: Strong positive c-erbB-2 immunoexpression in neoplastic cells of astrocytoma G2. Magn 400×.

Mentions: In group I, c-erbB-2 protein expression was observed in 15/17 cases (88.3%); 7 (41.2%) were (+) positive, and 8 (47.1%) cases were (++) positive (Figure 2). In 8 cases the immunohistochemical reaction was very intense in 80–90% of the neoplastic cells.


c-erbB-2 protein expression in astrocytic tumors of the brain.

Reszeć J, Bernaczyk PS, Milewski R, Chyczewski L, Mariak Z - Med. Sci. Monit. (2011)

Strong positive c-erbB-2 immunoexpression in neoplastic cells of astrocytoma G2. Magn 400×.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3539622&req=5

f2-medscimonit-17-8-br216: Strong positive c-erbB-2 immunoexpression in neoplastic cells of astrocytoma G2. Magn 400×.
Mentions: In group I, c-erbB-2 protein expression was observed in 15/17 cases (88.3%); 7 (41.2%) were (+) positive, and 8 (47.1%) cases were (++) positive (Figure 2). In 8 cases the immunohistochemical reaction was very intense in 80–90% of the neoplastic cells.

Bottom Line: There were no statistically significant differences between the examined groups.The strongest c-erbB-2 immunoexpression was observed in low grade astrocytomas (diffuse astrocytomas G2); in the glioblastoma group the c-erbB-2 protein expression was weak and 17.4% of cases were negative.C-erbB-2 protooncogene alteration is an early phenomenon in glial tumor development and progression.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland. joannareszec@gmail.com

ABSTRACT

Background: Astrocytic tumors are the primary brain tumors, which often progress to glioblastoma, a highly malignant neoplasm of the central nervous system. There is much new data regarding to the formation and progression of these tumors; however, glioblastoma remains one of the most fatal neoplasms in humans. The aim of the study was to evaluate the role of c-erbB-2 protein expression in various groups of astrocytic tumors.

Material/methods: 65 cases of astrocytic tumors were divided into 3 groups: diffuse astrocytoma (group I; n=17 cases), anaplastic astrocytoma (group II; n=23 cases) and glioblastoma (group III; n=25 cases). C-erbB-2 protein expression was estimated semiquantitatively on immunohistochemically stained tissue sections using antibodies against c-erbB-2 protein. Statistical analysis was performed in all examined groups.

Results: The c-erbB-2 protein expression was observed in 15 out of 17 cases (88.3%) in group I, 22 out of 25 cases (88%) cases in group II, and in 19 out of 23 cases (82.6%) in group III. There were no statistically significant differences between the examined groups. The strongest c-erbB-2 immunoexpression was observed in low grade astrocytomas (diffuse astrocytomas G2); in the glioblastoma group the c-erbB-2 protein expression was weak and 17.4% of cases were negative.

Conclusions: C-erbB-2 protooncogene alteration is an early phenomenon in glial tumor development and progression.

Show MeSH
Related in: MedlinePlus